FGI-106

FGI-106
Legal status
Legal status	US: Investigational New Drug ;
Identifiers
	IUPAC name N1,N7-bis[3-(dimethylamino)propyl]-3,9-dimethylquinolino[8,7-h]quinoline-1,7-diamine;
CAS Number	501081-38-5 ;
PubChem CID	432342;
ChemSpider	382357;
UNII	BRT994456W;
Chemical and physical data
Formula	C28H38N6
Molar mass	458.640 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CN(C)CCCNc(c2ccc14)cc(C)nc2c1ccc3c4nc(C)cc3NCCCN(C)C;
	InChI InChI=1S/C28H38N6/c1-19-17-25(29-13-7-15-33(3)4)23-11-10-22-21(27(23)31-19)9-12-24-26(18-20(2)32-28(22)24)30-14-8-16-34(5)6/h9-12,17-18H,7-8,13-16H2,1-6H3,(H,29,31)(H,30,32); Key:WJUPENLNVUCETH-UHFFFAOYSA-N;

FGI-106 is a broad-spectrum antiviral drug developed as a potential treatment for enveloped RNA viruses, in particular viral hemorrhagic fevers from the bunyavirus, flavivirus and filovirus families. It acts as an inhibitor which blocks viral entry into host cells. In animal tests FGI-106 shows both prophylactic and curative action against a range of deadly viruses for which few existing treatments are available, including the bunyaviruses hantavirus, Rift Valley fever virus and Crimean-Congo hemorrhagic fever virus, the flavivirus dengue virus, and the filoviruses Ebola virus and Marburg virus.[1][2][3][4][5]

References

Aman MJ, Kinch MS, Warfield K, Warren T, Yunus A, Enterlein S, et al. (September 2009). "Development of a broad-spectrum antiviral with activity against Ebola virus". Antiviral Research. 83 (3): 245–51. doi:10.1016/j.antiviral.2009.06.001. PMID 19523489.
Smith DR, Ogg M, Garrison A, Yunus A, Honko A, Johnson J, Olinger G, Hensley LE, Kinch MS (2010). "Development of FGI-106 as a broad-spectrum therapeutic with activity against members of the family Bunyaviridae". Virus Adaptation and Treatment: 9. doi:10.2147/VAAT.S6903.
Basu A, Li B, Mills DM, Panchal RG, Cardinale SC, Butler MM, et al. (April 2011). "Identification of a small-molecule entry inhibitor for filoviruses". Journal of Virology. 85 (7): 3106–19. doi:10.1128/JVI.01456-10. PMC 3067866. PMID 21270170.
Ippolito G, Feldmann H, Lanini S, Vairo F, Di Caro A, Capobianchi MR, Nicastri E (March 2012). "Viral hemorrhagic fevers: advancing the level of treatment". BMC Medicine. 10: 31. doi:10.1186/1741-7015-10-31. PMC 3325866. PMID 22458265.
Picazo E, Giordanetto F (February 2015). "Small molecule inhibitors of ebola virus infection". Drug Discovery Today. 20 (2): 277–86. doi:10.1016/j.drudis.2014.12.010. PMID 25532798.

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.